ChaoMu Medical Completes Series B Funding to Advance Innovative Ocular Neuromodulation Therapy

Recently, Super Vision Technology, Inc. (hereinafter referred to as "Super Vision") announced the completion of its Series B financing. This round of financing will help Super Vision further advance its technology research and development and market expansion, bringing good news to more patients with eye diseases.

Super Vision Technology, Inc. was established in 2018 as a globally-oriented enterprise specializing in the research and development of high-end ophthalmic medical devices and medical chips. The company is committed to creating star products in the global high-end medical device industry, contributing to China's scientific and technological innovation, and bringing light and new hope to patients worldwide.

Currently, the company's core product is a Class III active i-NYS implantable ocular muscle neurostimulator, which is mainly implanted through subcutaneous surgery behind the ear. The product contains a chip system that electrically stimulates the neuromuscular interface of the extraocular muscles, helping patients suppress abnormal nerve impulses, thereby addressing nystagmus issues.

Compared with traditional surgical treatment, the advantage of the i-NYS treatment lies in "not damaging the patient's ocular nerves and muscles, with stable efficacy and good long-term prognosis." At the 2024 annual meeting of the American Association for Pediatric Ophthalmology and Strabismus, Super Vision disclosed relevant data: 71 clinical trials verified that after i-NYS treatment, nystagmus frequency and amplitude could be reduced by about 80%, fixation time could be increased approximately fourfold, and patients' visual quality and quality of life could be significantly improved. Based on the current clinical trial results, in January 2024, i-NYS was approved to enter the National Medical Products Administration’s special review process for innovative medical devices; by the end of 2024, i-NYS officially submitted a registration application to the National Medical Products Administration and was accepted.

In the development of traditional neuromodulation medical devices (such as pacemakers, cochlear implants, vagus nerve stimulators, etc.), large size and heavy trauma are common issues, often leading to clinical challenges such as large surgical wounds, poor prognosis, and in-body rejection. Therefore, the current mainstream R&D trend internationally is to develop more miniaturized medical chip solutions.

"We have developed an ultra-small 3mmx3mm medical neuroregulation chip. In addition to our product, this chip can theoretically be applied to the miniaturization research and development of all medical devices. In January this year, the chip completed its second round of tape-out. One of our future goals is to create a research and development platform based on neuroregulation medical chips, applying this technology to the development of more neuroregulation products in the industry," said Wang Tianfang.

It is reported that, apart from the i-NYS implantable ocular muscle neurostimulator, Super Vision has also developed a pipeline of multiple products in the ophthalmic medical device sector, covering indications such as myopia prevention and correction, strabismus diagnosis, glaucoma, and presbyopia. Among these, the product for myopia treatment will enter clinical trials within this year and is expected to be launched in the market in the next 2-3 years.

Moreover, when discussing the热潮 of medical device companies going global in the past two years, Wang Tianfang stated that as a global innovative medical device R&D company, going global has always been one of Super Vision's core strategic directions. In 2022, Super Vision had already established a subsidiary in the United States. By continuously participating in professional ophthalmology conferences in the U.S. and expanding business resources over the years, the company has gathered a group of overseas experts and partners to jointly assist in the registration and application of products in the North American region. "In the future, Super Vision’s subsidiary will further develop independently through capitalization, allowing the 'China chip' to reach the world and serve more patients globally."